Fewer than half of screened ICU patients typically meet eligibility for an ARDS trial on any given day, and that number can fall further overnight when a site’s research staff isn’t present. That gap between theoretical screening capacity and actual enrollment is where most ARDS programs lose time, and it’s the operational problem a recently published case study from PSI CRO describes working through on behalf of a sponsor running a tight-deadline study.
The PSI account is specific about what drove site selection: not bed count or academic prestige, but a granular audit of ICU infrastructure, staffing coverage across all hours, real-world screening throughput, and how quickly a site could assess patient prognosis against protocol eligibility criteria. Those factors combined determine whether a site can actually convert a screen to a consent before the patient’s condition changes, which in ARDS can happen within hours. Sites that looked productive on paper routinely fell short when staffing gaps meant no one was available to initiate the consent process at 2 a.m.
Consent in ICU trials carries its own regulatory weight. ARDS patients are almost never able to consent for themselves, so studies depend on legally authorized representatives, a requirement the FDA’s guidance on emergency use of investigational products addresses directly. PSI’s approach built 24/7 study team availability into the site model so that when a representative arrived, the process could move without waiting for morning. That design choice isn’t novel, but executing it across multiple sites simultaneously under a compressed sponsor timeline is where most CROs stumble. ARDS also resists the usual enrollment math: as a peer-reviewed commentary in critical care literature notes, the condition’s heterogeneity means patient populations that look similar by diagnosis can differ enough biologically to distort results, making precise eligibility criteria both necessary and enrollment-limiting.
Approved pharmacological options for ARDS remain limited, with supportive care still the backbone of management, which means the field needs working trial infrastructure more than it needs better recruitment brochures. The concrete marker here is whether sponsors begin treating ICU staffing coverage as a primary site qualification variable rather than an operational footnote, because the PSI case suggests that single factor did more to protect enrollment continuity than any other design element.
Source link: https://psi-cro.com/ards-icu-clinical-trial-cro-case-study/
Moe Alsumidaie, MBA, MSF, is founder and Chief Editor of Vanguard Publications, which publishes Clinical Trial Vanguard, Pharma Vanguard and BullScope, and Head of Research at CliniBiz. He has two decades in clinical trial operations and data science, with earlier roles at Genentech, Abbott Vascular and Stanford University Medical Center, and is a guest lecturer in clinical trial sciences at Rutgers University.
